As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

GSK has escalated a dispute over rights to its cancer immunotherapy Jemperli, after its subsidiary Tesaro filed a complaint ...

Some four years into Jemperli’s commercial lifespan, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into ...

The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of ...

(Reuters) -Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of ...

AnaptysBio has separately alleged that GSK subsidiary Tesaro breached “certain requirements” under their 2014 license agreement involving a program that would become GSK's Jemperli.

UK pharma major GSK has announced that the National Institute for Health and Care Excellence (NICE) has issued final guidance ...

GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing ...

Merck’s Keytruda is well established as the standard treatment for newly diagnosed metastatic non-small cell lung cancer. For PD-1 latecomer GSK, that’s the benchmark its Jemperli must live up to—and ...

Saturday, GSK plc (NYSE:GSK) announced overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOT-EN6/GOG3031 ...

Jemperli plus standard-of-care chemotherapy with carboplatin and paclitaxel, followed by Jemperli plus Zejula as maintenance therapy produced a statistically significant and clinically meaningful ...